116 related articles for article (PubMed ID: 31693353)
1. Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate.
Zhang Z; Yu P; Gou Y; Zhang J; Li S; Cai M; Sun H; Yang F; Liang H
J Med Chem; 2019 Dec; 62(23):10630-10644. PubMed ID: 31693353
[TBL] [Abstract][Full Text] [Related]
2. Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin.
Wang J; Gou Y; Zhang Z; Yu P; Qi J; Qin Q; Sun H; Wu X; Liang H; Yang F
Mol Pharm; 2018 Jun; 15(6):2180-2193. PubMed ID: 29722993
[TBL] [Abstract][Full Text] [Related]
3. Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin.
Zhang Y; Zhang Z; Gou Y; Jiang M; Khan H; Zhou Z; Liang H; Yang F
J Inorg Biochem; 2017 Jul; 172():1-8. PubMed ID: 28395195
[TBL] [Abstract][Full Text] [Related]
4. Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier.
Gou Y; Zhang Y; Zhang Z; Wang J; Zhou Z; Liang H; Yang F
Mol Pharm; 2017 Jun; 14(6):1861-1873. PubMed ID: 28471669
[TBL] [Abstract][Full Text] [Related]
5. Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain.
Qi J; Zhang Y; Gou Y; Zhang Z; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2016 May; 13(5):1501-7. PubMed ID: 27017838
[TBL] [Abstract][Full Text] [Related]
6. Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer.
Gou Y; Zhang Y; Qi J; Chen S; Zhou Z; Wu X; Liang H; Yang F
Oncotarget; 2016 Oct; 7(41):67004-67019. PubMed ID: 27564255
[TBL] [Abstract][Full Text] [Related]
7. Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain.
Qi J; Gou Y; Zhang Y; Yang K; Chen S; Liu L; Wu X; Wang T; Zhang W; Yang F
J Med Chem; 2016 Aug; 59(16):7497-511. PubMed ID: 27441502
[TBL] [Abstract][Full Text] [Related]
8. Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment.
Zhang Z; Zhang J; Jiang M; Zhao L; Li S; Sun H; Yang F; Liang H
Mol Pharm; 2020 Apr; 17(4):1405-1414. PubMed ID: 32096645
[TBL] [Abstract][Full Text] [Related]
9. Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin-Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor Microenvironment.
Man X; Li S; Xu G; Li W; Zhu M; Zhang Z; Liang H; Yang F
J Med Chem; 2024 Apr; 67(7):5744-5757. PubMed ID: 38553427
[TBL] [Abstract][Full Text] [Related]
10. Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain.
Gou Y; Qi J; Ajayi JP; Zhang Y; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2015 Oct; 12(10):3597-609. PubMed ID: 26354410
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
12. Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin.
Gou Y; Zhang Z; Qi J; Liang S; Zhou Z; Yang F; Liang H
J Inorg Biochem; 2015 Dec; 153():13-22. PubMed ID: 26398432
[TBL] [Abstract][Full Text] [Related]
13. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin.
Zhang Y; Ho A; Yue J; Kong L; Zhou Z; Wu X; Yang F; Liang H
Eur J Med Chem; 2014 Oct; 86():449-55. PubMed ID: 25200980
[TBL] [Abstract][Full Text] [Related]
14. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
15. Human Serum Albumin-Platinum(II) Agent Nanoparticles Inhibit Tumor Growth Through Multimodal Action Against the Tumor Microenvironment.
Xu S; Luo W; Zhu M; Zhao L; Gao L; Liang H; Zhang Z; Yang F
Mol Pharm; 2024 Jan; 21(1):346-357. PubMed ID: 38015620
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the copper(II) complexes cytotoxicity to cancer cells through bound to human serum albumin.
Gou Y; Zhang Y; Qi J; Zhou Z; Yang F; Liang H
J Inorg Biochem; 2015 Mar; 144():47-55. PubMed ID: 25573806
[TBL] [Abstract][Full Text] [Related]
17. HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach.
Yang F; Liang H
Future Med Chem; 2016; 8(2):89-91. PubMed ID: 26824398
[No Abstract] [Full Text] [Related]
18. Water-soluble DNA minor groove binders as potential chemotherapeutic agents: synthesis, characterization, DNA binding and cleavage, antioxidation, cytotoxicity and HSA interactions.
Fu XB; Liu DD; Lin Y; Hu W; Mao ZW; Le XY
Dalton Trans; 2014 Jun; 43(23):8721-37. PubMed ID: 24770345
[TBL] [Abstract][Full Text] [Related]
19. Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Chen L; Zeng D; Xu N; Li C; Zhang W; Zhu X; Gao Y; Chen PR; Lin J
ACS Appl Mater Interfaces; 2019 Nov; 11(45):41889-41897. PubMed ID: 31615203
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
Kim I; Kim TH; Ma K; Lee ES; Kim D; Oh KT; Lee DH; Lee KC; Youn YS
Bioconjug Chem; 2010 Aug; 21(8):1513-9. PubMed ID: 20715855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
